Vaccine based on folded receptor binding domain‐PreS fusion protein with potential to induce sterilizing immunity to SARS‐CoV‐2 variants-Reference-Cited by-同舟云学术

Vaccine based on folded receptor binding domain‐PreS fusion protein with potential to induce sterilizing immunity to SARS‐CoV‐2 variants

Published:2022-04-15 Issue:8 Volume:77 Page:2431-2445
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Gattinger Pia¹^ORCID,Kratzer Bernhard²^ORCID,Tulaeva Inna¹³^ORCID,Niespodziana Katarzyna¹⁴^ORCID,Ohradanova‐Repic Anna⁵^ORCID,Gebetsberger Laura⁵^ORCID,Borochova Kristina¹,Garner‐Spitzer Erika⁶^ORCID,Trapin Doris²,Hofer Gerhard⁷,Keller Walter⁸^ORCID,Baumgartner Isabella⁹,Tancevski Ivan¹⁰^ORCID,Khaitov Musa¹¹¹²^ORCID,Karaulov Alexander³,Stockinger Hannes⁵^ORCID,Wiedermann Ursula⁶^ORCID,Pickl Winfried F.²⁴^ORCID,Valenta Rudolf¹³⁴¹¹^ORCID

Affiliation:

1. Department of Pathophysiology and Allergy Research Division of Immunopathology Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria

2. Center for Pathophysiology, Infectiology and Immunology Institute of Immunology Medical University of Vienna Vienna Austria

3. Laboratory for Immunopathology Department of Clinical Immunology and Allergology Sechenov First Moscow State Medical University Moscow Russia

4. Karl Landsteiner University of Health Sciences Krems Austria

5. Center for Pathophysiology, Infectiology and Immunology Institute for Hygiene and Applied Immunology Medical University of Vienna Vienna Austria

6. Institute of Specific Prophylaxis and Tropical Medicine Medical University of Vienna Vienna Austria

7. Department of Materials and Environmental Chemistry University of Stockholm Stockholm Sweden

8. Institute of Molecular Biosciences, BioTechMed Graz University of Graz Graz Austria

9. Department of Ophthalmology Medical University Vienna Vienna Austria

10. Department of Internal Medicine II Medical University of Innsbruck Innsbruck Austria

11. NRC Institute of Immunology FMBA of Russia Moscow Russia

12. Pirogov Russian National Research Medical University Moscow Russia

Funder

Austrian Science Fund

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.15305

Reference51 articles.

1. SARS‐CoV‐2 candidate vaccines ‐ composition, mechanisms of action and stages of clinical development

2. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

3. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

4. BarrettJR Belij‐RammerstorferS DoldC et al. Phase 1/2 trial of SARS‐CoV‐2 vaccine ChAdOx1 nCoV‐19 with a booster dose induces multifunctional antibody responses [published correction appears in Nat Med. 2021 Jun;27(6):1113].Nat Med. 2021;27(2):279‐288.

5. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential decline of SARS‐CoV‐2‐specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID‐19;Allergy;2024-07-14

2. Flow Cytometry-Based Measurement of Antibodies Specific for Cell Surface-Expressed Folded SARS-CoV-2 Receptor-Binding Domains;Vaccines;2024-04-01

3. Safety, immunogenicity, and protective effective of inhaled COVID‐19 vaccines: A systematic review and meta‐analysis;Journal of Medical Virology;2024-04

4. Construction by artificial intelligence and immunovalidation of hypoallergenic mite allergen Der f 36 vaccine;Frontiers in Immunology;2024-03-27

5. Vaccine Based on Recombinant Fusion Protein Combining Hepatitis B Virus PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived Receptor Binding Domain Strongly Induces Omicron-Neutralizing Antibodies in a Murine Model;Vaccines;2024-02-23